Diego Foschi1, Luca Sorrentino2, Igor Tubazio2, Consuelo Vecchio3, Tarcisio Vago4, Maurizio Bevilacqua5, Andrea Rizzi2, Fabio Corsi2. 1. Chair of General Surgery, Department of Biomedical and Clinical Sciences "Luigi Sacco", L. Sacco Hospital, University of Milan, via G. B. Grassi 74, 20157, Milan, Italy. Diego.Foschi@unimi.it. 2. Chair of General Surgery, Department of Biomedical and Clinical Sciences "Luigi Sacco", L. Sacco Hospital, University of Milan, via G. B. Grassi 74, 20157, Milan, Italy. 3. Unit of Dietetics, Department of Medicine, Luigi Sacco Hospital, via G. B. Grassi 74, 20157, Milan, Italy. 4. Endocrine Laboratory Unit, Department of Medicine, Luigi Sacco Hospital, via G. B. Grassi 74, 20157, Milan, Italy. 5. Unit of Endocrinology, Department of Medicine, Luigi Sacco Hospital, via G. B. Grassi 74, 20157, Milan, Italy.
Abstract
BACKGROUND: Randomized controlled trials have demonstrated that bariatric surgery is effective in obtaining remission of type 2 diabetes mellitus (T2DM) in obese patients, yet no data exist in the literature from prospective studies with ileal interposition with duodenal diversion sleeve gastrectomy (II-DD-SG). The aim of this case-control study is to investigate if II-DD-SG is superior to medical treatment in T2DM obese patients. METHODS: Thirty obese patients (BMI > 30) affected by T2DM were recruited for surgery (II-DD-SG) between 2008 and 2011 and were matched with an equal control group which received standard medical treatment. Anthropometric measures, glucose metabolism, cardiovascular risk factors were determined baseline and during follow-up. The primary end point was T2DM remission; reduction of body weight, BMI, and cardiovascular risk factors were secondary end-points. RESULTS: Shortly after II-DD-SG, normalization of glucose plasma levels and glycated hemoglobin was observed followed by a significant decrease in body weight and BMI. At one-year follow-up, insulin resistance strongly declined as did insulin plasma levels. Complete remission was observed in 26 patients (86%); 2 (6.6%) had partial remission, and two (6.6%) were still diabetic. After 5 years, 17 of 25 patients on follow-up (68%) showed complete remission of T2DM and 56% had remission of cardiovascular risk factors. Only two patients receiving medical treatment showed complete remission of T2DM (p < 0.0001 versus II-DD-SG). No significant changes of anthropometric parameters and lipid metabolism were recorded. CONCLUSIONS: II-DD-SG is an effective surgical procedure, able to induce complete and prolonged remission of T2DM in obese patients as opposed to medical treatment.
BACKGROUND: Randomized controlled trials have demonstrated that bariatric surgery is effective in obtaining remission of type 2 diabetes mellitus (T2DM) in obesepatients, yet no data exist in the literature from prospective studies with ileal interposition with duodenal diversion sleeve gastrectomy (II-DD-SG). The aim of this case-control study is to investigate if II-DD-SG is superior to medical treatment in T2DM obesepatients. METHODS: Thirty obesepatients (BMI > 30) affected by T2DM were recruited for surgery (II-DD-SG) between 2008 and 2011 and were matched with an equal control group which received standard medical treatment. Anthropometric measures, glucose metabolism, cardiovascular risk factors were determined baseline and during follow-up. The primary end point was T2DM remission; reduction of body weight, BMI, and cardiovascular risk factors were secondary end-points. RESULTS: Shortly after II-DD-SG, normalization of glucose plasma levels and glycated hemoglobin was observed followed by a significant decrease in body weight and BMI. At one-year follow-up, insulin resistance strongly declined as did insulin plasma levels. Complete remission was observed in 26 patients (86%); 2 (6.6%) had partial remission, and two (6.6%) were still diabetic. After 5 years, 17 of 25 patients on follow-up (68%) showed complete remission of T2DM and 56% had remission of cardiovascular risk factors. Only two patients receiving medical treatment showed complete remission of T2DM (p < 0.0001 versus II-DD-SG). No significant changes of anthropometric parameters and lipid metabolism were recorded. CONCLUSIONS: II-DD-SG is an effective surgical procedure, able to induce complete and prolonged remission of T2DM in obesepatients as opposed to medical treatment.
Authors: Philip R Schauer; Sangeeta R Kashyap; Kathy Wolski; Stacy A Brethauer; John P Kirwan; Claire E Pothier; Susan Thomas; Beth Abood; Steven E Nissen; Deepak L Bhatt Journal: N Engl J Med Date: 2012-03-26 Impact factor: 91.245
Authors: David E Cummings; David E Arterburn; Emily O Westbrook; Jessica N Kuzma; Skye D Stewart; Chun P Chan; Steven N Bock; Jeffrey T Landers; Mario Kratz; Karen E Foster-Schubert; David R Flum Journal: Diabetologia Date: 2016-03-17 Impact factor: 10.122
Authors: Bethany P Cummings; April D Strader; Kimber L Stanhope; James L Graham; Jennifer Lee; Helen E Raybould; Denis G Baskin; Peter J Havel Journal: Gastroenterology Date: 2010-03-10 Impact factor: 22.682
Authors: April D Strader; Torsten P Vahl; Ronald J Jandacek; Stephen C Woods; David A D'Alessio; Randy J Seeley Journal: Am J Physiol Endocrinol Metab Date: 2004-09-28 Impact factor: 4.310
Authors: Lena M S Carlsson; Markku Peltonen; Sofie Ahlin; Åsa Anveden; Claude Bouchard; Björn Carlsson; Peter Jacobson; Hans Lönroth; Cristina Maglio; Ingmar Näslund; Carlo Pirazzi; Stefano Romeo; Kajsa Sjöholm; Elisabeth Sjöström; Hans Wedel; Per-Arne Svensson; Lars Sjöström Journal: N Engl J Med Date: 2012-08-23 Impact factor: 91.245
Authors: Geltrude Mingrone; Simona Panunzi; Andrea De Gaetano; Caterina Guidone; Amerigo Iaconelli; Giuseppe Nanni; Marco Castagneto; Stefan Bornstein; Francesco Rubino Journal: Lancet Date: 2015-09-05 Impact factor: 79.321